Octavalent HPV with 15 mcg IMX / AAHS + Octavalent HPV with 30 mcg IMX / AAHS + Octavalent HPV with 60 mcg IMX / AAHS + Octavalent HPV with 120 mcg IMX / AAHS + Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Human Papilloma Virus
Conditions
Human Papilloma Virus, Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
Trial Timeline
Apr 1, 2006 → Nov 1, 2009
NCT ID
NCT00851643About Octavalent HPV with 15 mcg IMX / AAHS + Octavalent HPV with 30 mcg IMX / AAHS + Octavalent HPV with 60 mcg IMX / AAHS + Octavalent HPV with 120 mcg IMX / AAHS + Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)
Octavalent HPV with 15 mcg IMX / AAHS + Octavalent HPV with 30 mcg IMX / AAHS + Octavalent HPV with 60 mcg IMX / AAHS + Octavalent HPV with 120 mcg IMX / AAHS + Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™) is a phase 1 stage product being developed by Merck for Human Papilloma Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT00851643. Target conditions include Human Papilloma Virus, Cervical Cancer, Vulvar Cancer.
What happened to similar drugs?
14 of 20 similar drugs in Human Papilloma Virus were approved
Approved (14) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00851643 | Phase 1 | Completed |
Competing Products
20 competing products in Human Papilloma Virus